Table 1.
Clinicopathologic characteristics of enrolled CMC patients.
| Patient | Age, y | Weight, kg | Vol.; cm | Histopath. Type | Clinical Stage | Histo. Grade | Receptor Status | Adj. Ther. | OS, Days |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 13 | 28.9 | 6.3 | N/A | N/A | N/A | TN | No | 162 |
| P2 | 11 | 28.0 | 1.5 | Mixed carcinoma | I | I | ER+PR+HER2- | No | 501 ¥ |
| P3 | 10 | 5.5 | 4.2 | Comedocarcinoma | IV | II | ER+PR+HER2- | Yes | 133 |
| P4 | 11 | 2.1 | 3.4 | Mixed carcinoma | II | I | ER+PR+HER2- | No | 501 ¥ |
| P5 | 11 | 30.0 | 6.2; 5.4 † | Mixed carcinoma | V | II | TN ††; ER+PR+ | Yes | 386 |
| P6 | 9 | 7.2 | 3.5 | Mixed carcinoma | V | III | ER+PR+HER2- | Yes | 212 |
Histopath., histopathological tumor grade; Adj. Ther, adjuvant therapy; N/A, not available; †, right tumor; ††, the left tumor is triple-negative (TN), and the right tumor is ER+PR+. OS, overall survival counted from first treatment day up to 31 May 2024. ¥, dogs are alive.